Role of microRNA-141 in colorectal cancer with lymph node metastasis

LI FENG, HONGQING MA, LIANG CHANG, XINLIANG ZHOU, NA WANG, LIANMEI ZHAO, JING ZUO, YUDONG WANG, JING HAN and GUIYING WANG

1Department of Medical Oncology; 2Second Department of General Surgery; 3Department of Molecular Biology; 4Research Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China

Received March 3, 2015; Accepted May 19, 2016

DOI: 10.3892/etm.2016.3751

Abstract. The present study aimed to investigate the role of microRNA (miR)-141 in the pathogenesis of colorectal cancer (CRC). In total, 58 CRC patients were included in the present study. The mRNA and protein expression levels of mitogen-activated protein kinase 4 (MAP4K4) were detected by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blot analysis, respectively. The miRNA-141 expression was measured by RT-qPCR, while serum MAP4K4 content was detected by enzyme-linked immunosorbent assay. Natural killer (NK) cells and T cells in peripheral blood were detected by flow cytometry. The results indicated that the mRNA and protein expression levels of MAP4K4 were significantly elevated in the tumor tissues, lymph nodes (P<0.01) and serum (P<0.05) in CRC. Furthermore, the expression levels of MAP4K4 in CRC patients with lymph node metastasis were higher compared with those in patients without metastasis. Bioinformatics analysis revealed that MAP4K4 may be the target gene of miRNA-141. The expression levels of miRNA-141 in the tumor tissues, lymph nodes and serum were significantly decreased in CRC patients, with a more evident decline in cases with lymph node metastasis. In addition, the percentage of NK, CD3+ T and CD4+ T cells was significantly decreased, whilst the number of CD8+ T cells was significantly increased, in the peripheral blood in CRC. The present results showed that miRNA-141 was downregulated in CRC, which increased the expression levels of MAP4K4 and altered the anti-tumor response, further increasing the proliferation, invasion and metastasis of the tumors. These findings may contribute to improving the current understanding of the pathogenesis of CRC, and lead to the development of therapies involving miRNA-141.

Introduction

In China, the incidence and mortality rates of colorectal cancer (CRC) were 23.03/100,000 and 11.11/100,000, respectively, in 2011, ranking only after lung cancer and gastric cancer (1). As a result of early stage CRC not displaying typical symptoms and signs associated with the disease, patients are predominantly diagnosed at an advanced stage, often accompanied by metastasis, thus missing the optimal time-frame for effective treatment (2). In general, lymph node metastasis represents the first step of tumor dissemination for CRC, and lymph node micrometastasis is currently an accurate indicator for the clinical staging, treatment and prognostic determination of CRC (3). If the regional lymph nodes were not appropriately treated, the traditional radical lumpectomy of CRC alone may lead to inadequate or excessive chemotherapy, which may cause unwanted damage to normal organs and tissues. Therefore, lymph node metastasis in CRC has become an important research focus for the elucidation of disease pathogenesis and treatment, while the identification of the regulating factors involved has also attracted increasing attention.

The pathogenesis and development of CRC have been found to be regulated by various signaling pathways and other factors. For instance, it has been shown that homolog 8 (CBX8) and insulin-like growth factor-1 (IGF1) are closely associated with the onset of CRC (4), and microRNA (miRNA)-92 is a key oncogene in the development of the disease (5). Conversely, the status of the body’s immune system is also important for tumor proliferation and metastasis. The anti-tumor response is predominantly achieved by cellular immunity, and natural killer (NK) cells and T-lymphocyte subsets have been found to be implicated in tumor immune surveillance (6).

Mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4) is an upstream activator in the MAPK signaling pathway, which has been demonstrated to promote the invasion, metastasis and development of ovarian, breast and prostate cancer, and malignant melanoma (7-11). MAP4K4 has been demonstrated to be overexpressed in various tumors, accelerating tumor cell transformation, promoting cell invasion and decreasing cell adhesion (12). Furthermore, the expression of MAP4K4 in CRC without lymph node metastasis is significantly lower compared with lymph node metastasis, indicating the role of MAP4K4 in promoting CRC proliferation, invasion...
and metastasis (13). However, the effect of MAP4K4 on the immune system in CRC has yet to be fully elucidated.

In the present study, the role of miRNA-141 in the pathogenesis of CRC, especially concerning its regulation of MAP4K4, was investigated for the first time. The expression levels of MAP4K4 and miRNA-141 in the tumor, lymph nodes and serum of CRC patients were detected and analyzed, while the immune system in CRC was also evaluated.

Patients and methods

Patients. In total, 58 patients with CRC were included in the present study, who had been diagnosed and subjected to total surgical resection prior to radiotherapy at The Fourth Hospital of Hebei Medical University (Shijiazhuang, China) between January 2014 and December 2014. Disease diagnosis was based on the clinical presentation, medical history and family history, physical examination, laboratory tests, endoscopy, imaging detection, and histopathological examination (14). Of these patients, there were 5 cases of tubulovillous adenoma, 11 cases of papillary carcinoma, 21 cases of tubular adenocarcinoma, 13 cases of mucinous adenocarcinoma, 6 cases of signet ring cell carcinoma and 2 cases of undifferentiated carcinoma. The occurrence of lymph node metastasis was confirmed in 26 cases by postoperative pathological examination on biopsy, and the remaining 32 cases were free from lymph node metastasis. All patients were first-onset cases and had not previously received hormone therapy, radiotherapy or chemotherapy prior to surgery. In addition, 29 age- and gender-matched healthy individuals were enrolled into the control group. The CRC patients with lymph node metastasis included 11 males and 15 females, with ages of 34-85 years (median age, 61 years). CRC patients without lymph node metastasis included 17 males and 15 females, aged between 28-76 years (median age, 58 years). In the control group, there were 13 males and 16 females, aged from 22-72 years (median age, 55 years). Prior written and informed consent was obtained from each patient and the study was approved by the Ethics Review Board of the Fourth Hospital of Hebei Medical University.

Sample collection. The following specimens were collected from the subjects in the present study: i) The excised tumor and adjacent tissues, which were stored in liquid nitrogen; ii) the lymph nodes in proximity to the surgical site, which were stored in liquid nitrogen; and iii) the peripheral blood collected under fasting conditions in the morning, which was mixed with EDTA anticoagulant.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The mRNA expression levels of MAP4K4 and miRNA-141 were detected with the use of RT-qPCR. Briefly, for detection of the expression levels in tumor and in lymph nodes, total RNA was extracted with TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA). The serum RNA was extracted with the miRNeasy Serum/Plasma kit (Guangzhou Jianlun Biological Technology Co., Ltd., Guangzhou, China). RT was performed to obtain the cDNA with the RevertAid First Strand cDNA Synthesis kit (Fermentas; Thermo Fisher Scientific, Inc.), according to the manufacturer’s protocol. The 25 µl PCR system contained 2 liters template, 1 liter each primer, 12.5 liters TransStart Top Green qPCR SuperMix (Transgen Biotech, Inc., Beijing, China), and 8.5 liter double distilled H2O.

For the detection of MAP4K4, the primer sequences were as follows: MAP4K4 forward, 5'-AAGGAAGAGCGGGCGAGGTG-3', and reverse, 5'-TTGGTGCACCTGCTGAGAAGC-3'; GAPDH forward, 5'-GTTGGAGGTCCGAGTCAAGGGA-3', and reverse, 5'-GAGGGATCTGCTCGTGGAGA-3'. The PCR conditions consisted of denaturation at 94°C for 5 min, followed by 94°C for 30 sec, 60°C for 30 sec and 72°C for 45 sec, for a total of 35 cycles. For the detection of miRNA-141, the primer sequences were as follows: miRNA-141, 5'-CCG GTAACACTGTCTGGAA-3', and U6, 5'-GCTTCGGCA GCACATATAACTAAAT-3'. The PCR conditions were as follows: Denaturation at 95°C for 5 min, followed by 95°C for 15 sec, 58°C for 30 sec and 72°C for 30 sec, for 40 cycles. The relative expression levels of target genes were calculated with the 2-ΔΔCt method.

Western blot analysis. Normal, tumor and lymph node metastasis tissues were lysed on ice with lysis buffer (Beyotime Institute of Biotechnology, Haimen, China), and the protein concentration was determined with a BCA kit (cat. no. P0009; Beyotime Institute of Biotechnology). Protein samples (20 mg) were subjected to 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and then electronically transferred onto a nitrocellulose membrane. The blot was blocked with 5% non-fat milk at room temperature for 1 h, and then incubated with rabbit anti-human anti-MAP4K4 polyclonal primary antibody (1:1,000; cat. no. ab155583; Abcam, Cambridge, MA, USA) or rabbit anti-human anti-GAPDH polyclonal primary antibody (1:5,000; cat. no. ab9485; Abcam) at 4°C overnight. The membrane was then incubated with goat anti-rabbit immunoglobulin G (1:3,000; cat. no. ab6721; Abcam) at room temperature for 1 h. Subsequently, the blot was developed using an enhanced chemiluminescence system (cat. no. P0018A; Beyotime Institute of Biotechnology), and the protein bands were analyzed with Image Lab software version 3.0 (Bio-Rad Laboratories, Inc., Hercules, CA, USA).

Enzyme-linked immunosorbent assay (ELISA). Serum MAP4K4 contents were detected with an ELISA kit (cat. no. CSB-EL013439HU; Weijia Technology Co., Ltd., Guangzhou, China) according to the manufacturer's instructions. Blood sample was centrifuged at 4°C at 800 x g for 10 min, separating the serum from the blood cells. Sample (10 µl) was then added into the 96-well plates in the ELISA microplate, followed by the addition of 40 µl diluting solution. The experiment was performed in triplicate. Subsequently, 100 µl horseradish peroxidase-labeled antibody (contained within the ELISA kit) was added into each well, and the plate was placed in an incubator for 1 h. After washing five times with ddH2O, 50 µl substrate A and 50 µl substrate B were added into each well, respectively, and the plate was incubated at 37°C for 15 min. The reaction was stopped by adding 50 µl stopping solution, and the optical density at 450 nm was read on a microplate reader within 15 min.
Results

mRNA expression levels of MAP4K4 are elevated in the tumor tissues, lymph nodes and serum in CRC patients. In order to investigate the mRNA expression levels of MAP4K4 in the tumor tissues, lymph nodes and serum in CRC patients with or without lymph node metastasis, RT-qPCR was performed. The present results indicated that, compared with the control group, the mRNA expression levels of MAP4K4 were significantly elevated in the tumor tissues, lymph nodes and serum in patients with CRC (all \( P<0.05 \); Fig. 1). Furthermore, within the CRC patients, the mRNA expression levels of MAP4K4 in the tumor tissues, lymph nodes and serum in cases with lymph node metastasis were all significantly higher compared with those in cases without lymph node metastasis (\( P<0.05 \); Fig. 1). Thus, the results suggest that MAP4K4 may be upregulated in CRC, particularly in cases with lymph node metastasis, and this may contribute to the disease pathogenesis.

Protein expression levels of MAP4K4 are increased in the tumor tissues, lymph nodes and serum in CRC patients. The protein expression levels of MAP4K4 in the tumor tissues and lymph nodes were detected by western blot analysis, while the serum expression was detected by ELISA. The results of western blot analysis indicated that, compared with the control group, the protein expression levels of MAP4K4 were significantly increased in CRC tissues (\( P<0.05 \)) and more evidently in the lymph nodes (\( P<0.01 \); Fig. 2A and B). In addition, the protein expression levels of MAP4K4 in the tumor and lymph nodes in CRC patients with lymph node metastasis were all significantly higher compared with those without lymph node metastasis (\( P<0.05 \); Fig. 2A and B).

Similar results were obtained for the protein expression of MAP4K4 in the serum. ELISA analysis revealed that, compared with the control group, the serum MAP4K4 expression was significantly increased in CRC patients with and without lymph node metastasis (\( P<0.01 \)). However, the expression was elevated to a greater extent in the cases with lymph node metastasis compared with cases without metastasis (\( P<0.01 \); Fig. 2C). In accordance with the alteration of the mRNA expression levels of MAP4K4, the aforementioned results indicated that MAP4K4 may be involved in the pathogenesis of CRC, particularly in the development of metastasis via the lymphatic and blood circulation.

Expression levels of miRNA-141 are reduced in the tumor tissues, lymph nodes and serum in CRC patients. It has been reported that MAP4K4 may be regulated by miRNA-141 in cases of pancreatic cancer (16). To further investigate the underlying mechanisms through which MAP4K4 is modulated in CRC, bioinformatics analysis was performed. Results from the miRNA database, TargetScan, PiTa, RNAhybrid, and PICTA analyses revealed that MAP4K4 may be the target gene of miRNA-141 (Fig. 3), and may be involved in the pathogenesis of CRC. RT-qPCR was then performed to detect the expression levels of miRNA-141 in the tumor tissues, lymph nodes and serum from CRC patients. The current results demonstrated that, compared with the control group, the expression levels of miRNA-141 in the tumor tissues, lymph nodes and serum were significantly decreased in CRC patients (\( P<0.05 \); Fig. 4). Furthermore, the CRC patients, the expression levels of miRNA-141 in the tumor tissues, lymph nodes and serum in cases with lymph node metastasis decreased to a significant extent when compared with those in patients without lymph node metastasis (\( P<0.05 \); Fig. 4). The results suggest that miRNA-141 may participate in the underlying mechanisms.
in the pathogenesis and development of CRC, and contribute to lymph node metastasis.

**Discussion**

In the present study, the expression levels of MAP4K4 and the upstream miRNA-141 in the tumor tissues, lymph nodes and serum in patients with CRC with or without lymph node metastasis were investigated. In addition, the anti-tumor responses (as indicated by the NK cells and T-lymphocyte subsets) were also detected. The underlying mechanisms for the lymph node metastasis of CRC and the changes in the immune system, particularly those concerning the regulation of MAP4K4 by miRNA-141, were also discussed.

In 2011, >12 million cases were diagnosed with new-onset CRC worldwide, ranking third in terms of incidence in cases of malignant tumors in males, and only second to breast cancer in females (17,18). The primary treatment for CRC is surgical resection, combined with radiotherapy and chemotherapy, as well as molecular targeted therapy. However, the surgical cure rates and the postoperative survival rates are not satisfactory (19,20). The 5-year survival rate of CRC is associated with the local infiltration and regional lymph node metastasis. According to the American Joint Committee on Cancer (AJCC), CRC may be divided into stages II and III, based on the presence or absence of regional lymph node metastasis (21). Dukes’ staging (stages B and C) is also associated with the status of regional lymph node metastasis (22). Therefore, it is of great importance to screen for lymph node metastasis and to investigate the early-diagnosis molecular indicators for CRC.

The role of MAP4K4 in the pathogenesis of CRC was investigated in the present study. Dhillon *et al* (23) reported that MAP4K4 was able to activate p38 stress-activated protein kinase to enhance tumor proliferation. Wright *et al* (12) indicated that MAP4K4 was able to promote the malignant transformation,
the tumor tissues, lymph nodes, and serum in cases with lymph node metastasis. These results suggest that the downregulation of miRNA-141 may be associated with the proliferation, infiltration and metastasis of CRC. According to the present results concerning MAP4K4 in CRC, the upregulation of MAP4K4 may be associated with the downregulation of miRNA-141 in the development and progression of CRC. Considering the association between miRNA-141 and MAP4K4, as well as the important role of MAP4K4 in tumorigenesis, miRNA-141 expression (particularly in the serum) may be used as an indicator of CRC metastasis. The regional lymph node metastasis of CRC is known to result from the local tumor invasion; in addition, distant metastasis and/or metastasis into other organs is also observed (27,28). Accordingly, the downregulation of miRNA-141 may also contribute to the tumor dissemination into other organs and tissues.

In order to investigate the effects of miRNA-141 on the immune system, the NK and T cells in the peripheral blood of CRC patients were detected. The results demonstrated that the percentages of CD3+ and CD4+ T cells were significantly decreased, whereas the percentage of CD8+ T cells was significantly increased in CRC patients, resulting in a decreased CD4+/CD8+ ratio. Changes in the immune system were more evident in cases with lymph node metastasis, compared with the CRC patients without lymph node metastasis. NK cells and T lymphocytes represent the initial defense against tumors, thus, their dysfunction would weaken tumor resistance. The elevation in CD8 may result from the T lymphocytes induced by the tumor-secreted immunosuppressive factors (29,30), which may disturb the immune surveillance and facilitate the proliferation and metastasis of tumors. Therefore, these results suggest that the alterations in the immune system may be associated with the changes in miRNA-141 and MAP4K4 expression levels, which may contribute to the pathogenesis of CRC. Considering the various factors associated with the pathogenesis of CRC (31-33), and due to the limited number of subjects enrolled in the present study, further in-depth studies are required to investigate the detailed mechanisms through which miRNA-141 and MAP4K4 are involved in the development of CRC.

In conclusion, the current results showed that the mRNA and protein expression levels of MAP4K4 were elevated in the tumor tissues, lymph nodes and serum of CRC patients. The expression levels of MAP4K4 were higher in CRC patients with lymph node metastasis compared with those in patients without metastasis. Furthermore, the expression levels of miRNA-141 were reduced in the tumor tissues, lymph nodes and serum in CRC, with a more evident decline observed in cases with lymph node metastasis. In addition, the percentage of NK, CD3+ T, and CD4+ T cells was significantly decreased and that of CD8+ T cells was significantly increased in the peripheral blood of the CRC patients, resulting in significantly decreased CD4+/CD8+ ratios. The aforementioned findings may contribute to an improved understanding of the pathogenesis of CRC and provide evidence for the application of therapies involving miRNA-141.

Acknowledgements

The present study was supported by the Key Projects of Medical Sciences from the Hebei Provincial Department of Health (grant no. 20150769).
References


